BioVentrix

United States - San Ramon, CA

• 14/04/2023
• Series A
• $48,500,000

BioVentrix is a privately held medical device company headquartered in San Ramon, CA, USA. Our mission is to improve and expand the treatment available for congestive heart failure (CHF) caused by ischemic cardiomyopathy, through the development of less invasive, catheter-based approaches.

BioVentrix offers benefits to all stakeholders in heart failure:

Patient – improved survival and QOL by treating the underlying cause of HF less invasively
Payor – reduced hospitalizations and avoidance of more expensive, highly invasive procedures like transplant and LVAD
Provider – become a pioneer in heart failure and offer unique solutions to your patients, in the growing and most expensive disease state in the world

Related People

Jim DillonFounder

United States - Greater Boston

CHIEF EXECUTIVE OFFICER

EXPERIENCED LEADER

Executive Leadership & Vision | Early/Mid/Late Stage Financing | Extensive Global Cardiovascular Startup Experience | Strategic Business Development | Market Creation & Clinical Adoption | Capital & Commercial Team Execution | Create & Establish New Standard of Care | Clinical/Regulatory Development

Identify market opportunities with enormous clinical unmet needs and significant healthcare economic burdens. Champion vision and financing strategies. Drive proprietary innovation, world-wide market development and new technology adoption. Build high-performance elite global commercial teams. Develop and leverage KOL relationships; heart failure, structural heart/interventional cardiology & cardiac surgery.

LinkedIn https://www.linkedin.com/in/dillonjim/